Rationalizing the Study of Intratumoral Immunotherapy in Breast Cancer Origin Liver Metastases
Jason Williams, MD, the director of Interventional Oncology and Immunotherapy oncologist at the Williams Cancer Institute, discusses a study in which an immunotherapy combination was administered intratumorally to patients with liver metastases linked to breast cancer, which he presented in a poster at the 2019 Society of Immunotherapy of Cancer Annual Meeting.
Jason Williams, MD, the director of Interventional Oncology and Immunotherapy at the Williams Cancer Institute, discusses a study in which an immunotherapy combination was administered intratumorally to patients with liver metastases linked to breast cancer, which he presented in a poster at the 2019 Society of Immunotherapy of Cancer (SITC) Annual Meeting.
A preclinical study in mouse models, which was led by Ronald Levy at Stanford University, showed synergy between α-OX40 and CpG. This study served as a rationale for Williams and his colleague to recreate the study in humans.
The immunotherapy combination used for the in-human study was α-OX40, CpG, ipilimumab (Yervoy), and ketorolac. Ipilimumab was added to the combination to address the complexity of treating human subjects compared with mouse subjects, and this improved the success rate of the study overall.
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
